These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 3107042)

  • 1. L-dopa causes an acute, partial and reversible reversal of denervation-induced supersensitivity of striatal dopaminergic receptors.
    Ferre S; Casas M; Cobos A; Garcia C; Jane F; Grau JM
    Psychopharmacology (Berl); 1987; 91(2):254-6. PubMed ID: 3107042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3-O-methyl-DOPA is not involved in the development of behavioral supersensitivity after repeated L-dopa administration in 6-OHDA lesioned rats.
    Bräutigam K; Sohr R; Morgenstern R
    Behav Brain Res; 1994 Jul; 63(1):41-5. PubMed ID: 7945976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine receptor changes in response to prolonged treatment with L-dopa.
    Groppetti A; Flauto C; Parati E; Vescovi A; Rusconi L; Parenti M
    J Neural Transm Suppl; 1986; 22():33-45. PubMed ID: 2946813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of opiates in striatal D-1 dopamine receptor supersensitivity induced by chronic L-dopa treatment.
    Groppetti A; Ceresoli G; Mandelli V; Parenti M
    J Pharmacol Exp Ther; 1990 Jun; 253(3):950-6. PubMed ID: 2162953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioural and biochemical alterations in the function of dopamine receptors following repeated administration of L-DOPA to rats.
    Hall MD; Cooper DR; Fleminger S; Rupniak NM; Jenner P; Marsden CD
    Neuropharmacology; 1984 May; 23(5):545-53. PubMed ID: 6539859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Supersensitivity of the cholinergic response to apomorphine in the striatum following denervation or disuse supersensitivity of dopaminergic receptors in the rat.
    Consolo S; Ladinsky H; Samanin R; Bianchi S; Ghezzi D
    Brain Res; 1978 Oct; 155(1):45-54. PubMed ID: 210895
    [No Abstract]   [Full Text] [Related]  

  • 7. Early L-dopa treatment initially retards but later enhances dopamine receptor supersensitivity following unilateral dopamine denervation.
    Carey RJ; Pinheiro-Carrera M; Tomaz C; Huston JP
    Brain Res; 1994 Sep; 658(1-2):145-54. PubMed ID: 7834335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic treatment with 1-dopa plus carbidopa in hemitransected rats: preferential effects at intact dopamine synapses leading to behavioural signs of dopamine receptor supersensitivity.
    Agnati LF; Fuxe K; Calza L; Zini I; Benefenati F; Farabegoli C; Goldstein M
    Acta Physiol Scand; 1983 May; 118(1):27-34. PubMed ID: 6137934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.
    Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD
    Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioral quantification of striatal dopaminergic supersensitivity after bilateral 6-hydroxydopamine lesions in the mouse.
    Mandel RJ; Wilcox RE; Randall PK
    Pharmacol Biochem Behav; 1992 Feb; 41(2):343-7. PubMed ID: 1574523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Supersensitivity to dopamine agonists following unilateral, 6-hydroxydopamine-induced striatal lesions in mice.
    Thornburg JE; Moore KE
    J Pharmacol Exp Ther; 1975 Jan; 192(1):42-9. PubMed ID: 1168250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of chronic bromocriptine and L-dopa on spiperone binding and apomorphine-induced stereotypy.
    Globus M; Bannet J; Lerer B; Belmaker RH
    Psychopharmacology (Berl); 1982; 78(1):81-4. PubMed ID: 6815701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of chronic L-dopa treatment on the recovery of motor function in 6-hydroxydopamine-lesioned rats receiving ventral mesencephalic grafts.
    Blunt S; Jenner P; Marsden CD
    Neuroscience; 1991; 40(2):453-64. PubMed ID: 1902916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The sialagogue response of striatal dopamine receptors to L-dopa is not influenced by castration or chronic estrogen treatment.
    Pazo JH; Gomez-Gonzales M; Tumilasci OR; O'Donnell P; Murer G
    Brain Res Bull; 1986 Jan; 16(1):1-4. PubMed ID: 3955384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rotational behaviour in rats with unilateral striatal kainic acid lesions: a behavioural model for studies on intact dopamine receptors.
    Schwarcz R; Fuxe K; Agnati LF; Hökfelt T; Coyle JT
    Brain Res; 1979 Jul; 170(3):485-95. PubMed ID: 37986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined administration of direct dopamine receptor agonists and L-dopa does not interfere with utilization of exogenous L-dopa in rat corpus striatum.
    Globus M; Melamed E
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(2-3):211-5. PubMed ID: 6310691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid reversal of denervation supersensitivity of dopamine D1 receptors by l-dopa or a novel dopamine D1 receptor agonist, A68930.
    Britton DR; Kebabian JW; Curzon P
    Eur J Pharmacol; 1991 Jul; 200(1):89-93. PubMed ID: 1685124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of chronic lithium treatment on dopamine receptors in the rat corpus striatum. II. No effect on denervation or neuroleptic-induced supersensitivity.
    Staunton DA; Magistretti PJ; Shoemaker WJ; Deyo SN; Bloom FE
    Brain Res; 1982 Jan; 232(2):401-12. PubMed ID: 6322915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are the catecholestrogens involved in estrogen-induced striatal dopamine receptor supersensitivity?
    Ferretti C; Ghi P; Blengio M; Gaietta G; Barrera G; Genazzani E
    Eur J Pharmacol; 1989 Jul; 166(2):149-56. PubMed ID: 2551698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.